TRBV19
T cell receptor beta variable 19
Also known as: TCRBV17S1A1T, TCRBV19S1, TVB19_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A0A075B6N1
- Gene
- TRBV19
- Ensembl
- ENSG00000211746
- Chromosome
- 7
- Canonical length
- 114 aa
- Protein class
- Predicted intracellular proteins, T-cell receptor genes
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to be involved in cell surface receptor signaling pathway. Part of alpha-beta T cell receptor complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
114 residues, UniProt reviewed canonical sequence.
>A0A075B6N1|TRBV19
1 MSNQVLCCVV LCLLGANTVD GGITQSPKYL FRKEGQNVTL SCEQNLNHDA MYWYRQDPGQ
61 GLRLIYYSQI VNDFQKGDIA EGYSVSREKK ESFPLTVTSA QKNPTAFYLC ASSILocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRBV19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Highest tissue expression
- 50 nTPM
Expression across tissuesHPA
Tissue
- thymus: 50 nTPM
- lymph node: 27 nTPM
- appendix: 5.3 nTPM
- spleen: 3.6 nTPM
- gallbladder: 3.5 nTPM
- small intestine: 2.8 nTPM
Single-cell type
- t-cells: 0.2 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
Immune cell
- T-reg: 89 nTPM
- naive CD4 T-cell: 71 nTPM
- naive CD8 T-cell: 54 nTPM
- memory CD4 T-cell: 51 nTPM
- memory CD8 T-cell: 40 nTPM
- total PBMC: 16 nTPM
Brain region
- cerebral cortex: 0.9 nTPM
- white matter: 0.9 nTPM
- pons: 0.6 nTPM
- cerebellum: 0.4 nTPM
- medulla oblongata: 0.4 nTPM
- basal ganglia: 0.3 nTPM
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRBV19 as an antibody target. Whether an autoantibody or antibody against TRBV19 could matter depends on whether native TRBV19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRBV19 is annotated at the cell surface, where native TRBV19 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRBV19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...